EDC and ePRO Report from ISR Shows Maturing Market, Provides Tool for Clinical Outsourcing
Industry Standard Research
(ISR) today announced the release of a new market research report titled “
EDC and ePRO Market Trends and Service Provider Performance
.” This report provides the pharmaceutical industry and its service providers with novel insights into the current and future use of these technologies and enables better technology provider selection.
“From a classical market development point of view, EDC technology has finally ‘crossed the chasm’ and has become the de facto data collection mechanism for clinical trials,” Andrew Schafer, President of ISR explained. “While ePRO does not start from the same vantage point – not all studies need a patient-reported outcome component – we do see the ePRO market maturing and several products beginning to emerge as market leaders.”
ISR’s study surveyed 101 site-coordinators and principal investigators with responsibility for data collection at their sites. The data ISR captured represent 710 on-the-ground service experiences across 20 EDC and 14 ePRO products.
“With this data, sponsors can make more informed outsourcing decisions, improve relationships with sites by utilizing technology platforms they prefer, and build efficiencies into study designs,” Schafer explained. “For service providers, this ‘Voice-of-the-Customer’ research offers unique product satisfaction data from end-users on their product and their competitors.”
In addition to end-user satisfaction data, ISR’s report also provides service providers with important insights into current and future EDC and ePRO market trends, including: adoption, usage, preference, study penetration by Phase, and the new ‘eClinical’ service many large CROs are beginning to offer that is sure to impact the competitive landscape.
For more information about ISR’s report, please visit its website
here
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
